جست‌وجوی استاد و پژوهشگر

• Mitochondrial fatty-acid β-oxidation
• Post-translational redox modifications
• Nitric-oxide signalling
• +۶ مورد دیگر

Paschalis-Thomas Doulias is Associate Professor of Organic Chemistry and Biochemistry in the Department of Chemistry at the University of Ioannina, Greece. His laboratory, located in Ioannina Campus building X3-106D, investigates the molecular mechanisms governing mitochondrial fatty-acid β-oxidation and their translational exploitation for rare inherited disorders of long-chain fatty-acid oxidation. Research Interests His research spans two tightly integrated themes: Basic Research: Elucidating post-translational redox modifications—particularly S-nitrosylation, acetylation and succinylation—that regulate key enzymes of mitochondrial fatty-acid oxidation. Work uses genetically modified mouse models (Sirt-3 -/- , Sirt-5 -/- , eNOS -/- and VLCAD Cys238Ala knock-in) complemented by cellular mutagenesis to dissect how energetic demand is coupled to enzymatic flux. Translational Research: Developing nitric-oxide-based therapies for long-chain fatty-acid oxidation disorders (LC-FAODs). The group pioneered the concept that augmenting NO signalling restores catalytic efficiency of mutant VLCAD, and is currently validating FDA-approved NO donors and proprietary hybrid NO-plus-substrate molecules in patient-derived cells and a humanised VLCAD-deficient mouse. Publication Landscape (2020-2025) Over the past five years, Doulias and collaborators have generated 15 high-impact articles that collectively map redox-proteomic landscapes in cardiovascular, neurodegenerative and metabolic disease contexts. Recurring keywords include S-nitrosylation, TCA-cycle compromise, mitochondrial energetics, HFpEF, ALS and Alzheimer’s disease, underscoring a unifying theme of redox-metabolic crosstalk. Scientific Awards & Recognition While specific honours are not enumerated, the consistent citation of his work (H-index 30, 3571 citations) attests to significant peer recognition. Funding & Collaborations Active translational projects include medicinal-chemistry optimisation of NO-donating compounds and in vivo efficacy testing in humanised mouse models of VLCAD deficiency, implying sustained competitive funding and multi-disciplinary partnerships. Laboratory & Team The group operates within the Department of Chemistry core facilities, leveraging state-of-the-art proteomics, metabolomics and transgenic animal resources to advance both basic and pre-clinical goals.

Mariana Angoa-Perezمشاهده پروفایل

استادیار

• Neuroscience
• Neurotoxicology
• Behavioral Neuroscience
• +۴ مورد دیگر

Mariana Angoa-Perez serves as Assistant Professor in the Department of Physiology at Wayne State University, conducting interdisciplinary research at the intersection of neuroscience, neurotoxicology, and gut-brain axis interactions with emphasis on neuropathological mechanisms. Her academic credentials include: B.S. in Biology, Autonomous University of Puebla, Mexico (2003) Ph.D. in Biomedical Sciences, National Autonomous University of Mexico (2007) Post Doctoral Fellow in Psychiatry and Behavioural Neurosciences, Wayne State University (2008-2011) Visiting Research Fellow, Henry Ford Health System, William T Gossett Neurology Laboratories (2004-2005) Dr. Angoa-Perez's research program integrates animal behavior, molecular neurochemistry, and bioinformatics to investigate neurotoxic effects of environmental agents (ozone, nerve agents, substituted amphetamines) on monoamine systems, with recent emphasis on gut microbiome influences in Gulf War Illness, traumatic brain injury, and substance use disorders. Her methodological expertise spans histopathology, 16S rRNA sequencing, and behavioral assessments for anxiety, depression, and psychostimulant responses. Publication analysis reveals a strategic research evolution from classical neurotoxicology (2018-2019 cathinone studies) toward contemporary microbiome-neurology interfaces (2020-2021 Gulf War Illness and TBI models), demonstrating consistent application of transgenic models (TPH2 knockouts) and multi-omics approaches. Current work focuses on bidirectional gut-brain communication pathways in neuropathology using high-fat diet interventions and neurotoxin exposure paradigms.

Anna Moszczynskaمشاهده پروفایل

دانشیار

• Addiction and Substance Abuse
• Neuropharmacology
• Neurodegenerative Diseases
• +۳ مورد دیگر

Dr. Anna Moszczynska is an Associate Professor in the Pharmaceutical Sciences Department at Wayne State University within the College of Pharmacy and Health Sciences . Her academic journey includes advanced degrees in Chemical Engineering (1988, Technical University of Lodz, Poland) Cell Biology (1995, University of Toronto, Canada) Neurochemistry (2002, University of Toronto, Canada) Postdoctoral training at Center for Addiction and Mental Health (2005), University of Guelph (2007), and Boston University (2008). Her research focuses on Addiction and Substance Abuse , Neuropharmacology , and Neurodegenerative Diseases , particularly investigating Parkin and Proteasome as molecular drug targets in Methamphetamine Use Disorder (MUD) Transposable Elements (rat LINE-1 and Identifier elements) in METH neurotoxicity using rat models and techniques like 2D gel electrophoresis , Co-immunoprecipitation , In Vivo Gene Transfer , and Proteomic Analysis . Recent publications highlight her work on parkin-deficient models (2021, 2025), epigenetic mechanisms (2023), and protein interaction networks (2024, 2025). Her studies explore METH-induced transcriptomic changes , VMAT2 interactions , and neurochemical biomarkers .

Shane Perrineمشاهده پروفایل

استادیار

• Neuropsychopharmacology
• Drug Addiction
• Co-occurring Psychiatric Conditions
• +۵ مورد دیگر

Shane Perrine is an Assistant Professor in the Department of Psychiatry at Wayne State University School of Medicine. His research focuses on the neuropsychopharmacology of drug addiction and co-occurring psychiatric conditions, particularly depression and anxiety. Dr. Perrine's laboratory investigates how drugs, especially psychostimulants like cocaine, methamphetamine, and MDMA (ecstasy), affect neurochemistry and behavior. Using animal models, his work aims to elucidate the mechanisms of brain plasticity in response to acute and repeated drug exposure, stressors, and cues that lead to anxiety, depression, and relapse to drug seeking. His current research has two main directions: (1) determining the neurochemical underpinnings disrupted by psychostimulants that lead to anxiety, depression, and maladaptive reward behaviors; and (2) understanding the neurobiological basis underlying the comorbidity of PTSD and drug abuse. Dr. Perrine's recent publications reveal strong trends in neurobiological mechanisms of addiction with emphasis on sex differences, neuronal ensembles, and the intersection between PTSD and substance use disorders. His work frequently employs rodent models combined with behavioral testing, advanced neuroimaging, and molecular techniques. A significant portion examines how traumatic brain injury and stress exposure interact with substance use, including investigations into opioid exposure during pregnancy and its developmental consequences. Dr. Perrine teaches several courses including Molecular Neuropsychopharmacology (PYC7010), Neurobiology of Addiction (NEU4200), and Fundamentals of Neuroimaging (PYC7140). He collaborates with numerous researchers within Wayne State University and at other institutions including University of Arkansas, Emory University, University of Michigan, and Temple University. His laboratory employs methodologies including rodent models for reward, anxiety, and depression-related behaviors, western blotting, ELISA, HPLC, and proton-magnetic resonance spectroscopy. His primary disease/disorder focus is drug abuse and dependence, anxiety, and depression, with rats serving as the primary model species.

• Behavioral Neuroscience
• Psychopharmacology
• Substance Use Disorders
• +۵ مورد دیگر

Chana Akins, Ph.D., is a full Professor of Psychology and a leading behavioral neuroscientist whose federally-funded program explores how drugs of abuse alter natural reward circuits underlying sexual motivation, associative learning, and inhibitory control. Active in both the Neuroscience and Substance Use Research Priority Areas, she has published 51 peer-reviewed works since 1990, secured multiple NIDA grants, and earned prestigious honors including APA Fellow and the Clifford T. Morgan Distinguished Service Award. Education: Ph.D. Psychology, University of Texas at Austin (1994) M.S. Psychology, Texas Tech University (1989) B.S. Psychology, Texas Tech University (1987) Research Focus: Dr. Akins integrates in-vivo pharmacology, Pavlovian conditioning, and comparative models—primarily Japanese quail—to dissect how ethanol, cocaine, methamphetamine and nicotine hijack sexual reward pathways and executive control. Recent work extends these questions to human drinkers using crowdsourced digital tasks, bridging animal and clinical translation. Publication Trends: Across 2022-2024 her laboratory has elucidated dose-dependent ethanol reward/aversion in quail, identified glucocorticoid receptor modulation of sign-tracking, revealed sex-specific alcohol metabolism, and demonstrated alcohol-cue disruption of inhibitory control in heavy drinkers—highlighting a trajectory from mechanism to human behavior. Honors & Awards: Fellow, American Psychological Association (2014) Clifford T. Morgan Distinguished Service Award, APA Div. 6 (2011) Fellow, American Council on Education (2018) Women’s Executive Leadership Development (WELD) Honoree (2017) Academic Leadership Academy (BHEC) Recognition (2016) Grants & Leadership: As PI or Co-I on five major federal/university grants totaling >$5M, she has directed projects ranging from prenatal cocaine effects on sexual motivation to normative crowdsourced alcohol-cognition data. She has served in editorial, review, and governance roles for APA, NIDA study sections, and university strategic councils. Labs & Teams: Dr. Akins heads an active research group that maintains avian vivaria, behavioral pharmacology suites, and collaborative links with clinical alcohol researchers, supporting training for graduate students, post-docs, and undergraduates across psychology, neuroscience, and animal sciences.

• Substance Abuse
• Pharmacology
• Neuropsychopharmacology
• +۲ مورد دیگر

Joseph Alcorn is a Researcher specializing in substance abuse and pharmacotherapy . His work focuses on clinical psychopharmacology, particularly drug combinations for treating methamphetamine-use disorder and cannabis-related behaviors. Affiliation: Substance Use Priority Research Area Expertise: Neuropsychopharmacology, Behavioral Science, Clinical Research In 2021, he co-authored a study in Experimental and Clinical Psychopharmacology on pregabalin maintenance in daily cannabis users, highlighting his interest in pharmacological interventions for substance use disorders. His research output aligns with clinical studies and behavioral neuroscience. Key Collaborator: National Institute on Drug Abuse (2019–2021) h-index: 3 (based on citations from PlumX and Pure)

• Psychiatry
• Disaster Mental Health
• Trauma Psychology
• +۷ مورد دیگر

Dr. Şeyma SEHLİKOĞLU serves as an Assistant Professor in the Department of Internal Medical Sciences at Adiyaman University Faculty of Medicine. She completed her medical education at Gaziantep University (2007-2014) followed by medical specialization in Psychiatry at Adiyaman University (2016-2021). Her research primarily focuses on disaster mental health, with significant contributions examining the psychological impacts of the February 2023 Kahramanmaraş earthquakes in Turkey. She investigates PTSD, prolonged grief disorder, suicide risk, and various psychiatric outcomes in earthquake survivors, particularly those with physical injuries or limb loss. Additional research interests include anxiety disorders, psychotic disorders, forensic psychiatry, and substance use disorders. Dr. SEHLİKOĞLU has published extensively, with 32 articles, 6 books, and 25 conference proceedings to her name. Her recent work (2023-2025) demonstrates a strong emphasis on the mental health consequences of natural disasters, with multiple studies examining specific populations including healthcare workers, postpartum women, and individuals with physical disabilities following the earthquakes. She teaches a comprehensive range of psychiatric subjects including Forensic Psychiatry, Schizophrenia Spectrum Disorders, Anxiety Disorders, Psychiatric Ethics, and Neurocognitive Disorders. Her clinical work includes serving as a Psychiatrist at the TC Ministry of Health Adiyaman University Training and Research Hospital (2021-2023) before transitioning to her current academic position. Dr. SEHLİKOĞLU is an active member of the Turkish Psychiatric Association and serves on the Education and Training Commission at Adiyaman University (2023-2024). Her current research projects focus on psychoeducation programs for substance use disorder following disasters and forensic evaluations of domestic violence perpetrators.

• Neuropsychopharmacology
• Neurocognition
• Behavioural performance
• +۷ مورد دیگر

Associate Professor Amie Hayley is a Senior Research Fellow at Swinburne University of Technology's School of Health Sciences and an NHMRC and Rebecca L. Cooper Al & Val Rosenstrauss Fellow at the Centre for Mental Health and Brain Sciences. She was named a 2024 Australasian College of Road Safety (ACRS) Road Safety Future Leader for her groundbreaking work on drug-impaired driving. As the Founding Chair of the Driver Monitoring System working group and Treasurer for the International Council for Alcohol, Drugs and Traffic Safety (ICADTS) Executive Board, she plays a significant international leadership role in road safety research. Dr. Hayley earned her Doctor of Philosophy (Medicine) from Deakin University, following a Bachelor of Psychological Studies (Honours) and a standard Bachelor of Psychological Studies, both from Victoria University. Her educational background provided the foundation for her current research program focused on the intersection of neuroscience, pharmacology, and road safety. Her research program investigates biochemical-physiological-behavioral pathways relevant to oculomotor function, visual-attentional performance, and information processing capabilities under drug conditions. With research funding exceeding AUD $6.4 million in the past 5 years, she leads multiple projects examining the effects of substances like cannabis, methamphetamine, and alcohol on driving performance. Her work uniquely combines laboratory-based psychopharmacology with real-world road safety applications, particularly through the development and validation of eye-tracking technologies for impairment detection. Analysis of her recent publications (2024-2025) reveals a strong focus on translational research bridging laboratory findings with practical road safety applications. Her work spans from basic pharmacological studies on drug interactions to population-level surveys on public attitudes toward drug-impaired driving. A notable trend is her increasing focus on medicinal cannabis and its implications for driving safety, reflecting emerging policy challenges in jurisdictions where cannabis is being legalized for medical use. Australasian College of Road Safety (ACRS) Future Leader in Road Safety (2024) Director, Communications and Media Award (2024) Vice-Chancellor's Research Excellence Award (Early Career) (2020) Australian Research Council's Engagement and Impact Assessment (2019) Young Scientist Award from International Council on Alcohol, Drugs and Traffic Safety (2019) Deans Award for Emerging Researcher (2016) Associate Professor Hayley actively supervises PhD students on projects related to alcohol hangovers, medicinal cannabis and driving, and sleep pharmacology. Her research program involves collaborations with government agencies including the Department of Transport and Planning (Victoria), Department of Treasury (ACT), and multiple industry partners, particularly Seeing Machines Limited with whom she has conducted several eye-tracking studies. Her work directly informs road safety policy through her leadership roles in ICADTS and engagement with policymakers on drug-impaired driving legislation. While not formally named in the materials, her research group functions as a multidisciplinary team bringing together expertise in neuroscience, pharmacology, psychology, and engineering to address the complex challenge of drug-impaired driving. The team utilizes advanced technologies including automotive-grade driver monitoring systems, eye-tracking equipment, and clinical research methodologies to produce evidence that directly informs road safety policy and practice.

• Hermeneutics
• Hermeneutic Constructivism
• Paediatric Illness Experience
• +۷ مورد دیگر

Blake Peck is a Senior Lecturer in the School of Nursing, Midwifery & Healthcare at the Faculty of Health, Federation University Australia, where he has held continuous academic employment since 2003. His scholarly work centers on qualitative methodologies, particularly hermeneutic constructivism, and the lived experiences of children with chronic illnesses within healthcare contexts. Peck completed his doctoral studies at the University of Ballarat between 2005 and 2013, establishing the foundation for his research in pediatric health and nursing education. His academic journey reflects deep commitment to advancing qualitative research frameworks in healthcare settings. His primary research interests include Hermeneutics, Hermeneutic Constructivism, Paediatric Illness Experience, Child Health Nursing, and Qualitative Inquiry. Peck has made significant contributions to understanding nursing student resilience, mental health interventions (including yoga-based programs), emergency nursing during the pandemic, and child health in rural Australia. His work consistently bridges theoretical frameworks with practical healthcare applications, emphasizing authentic understanding of patient and practitioner experiences. Analysis of his recent publications (2024-2025) reveals dominant trends in nursing education, mental health interventions, and pediatric care. He frequently employs qualitative and mixed-methods designs to investigate yoga for student wellbeing, emergency department utilization patterns, pandemic impacts on emergency nurses, and determinants of child health. His research demonstrates methodological rigor in hermeneutic approaches while addressing critical gaps in rural healthcare access and nursing workforce sustainability.

Gurudutt Pendyalaمشاهده پروفایل

استاد

• Neuroinflammation
• Psychostimulant Drugs
• Prenatal Drug Exposure
• +۶ مورد دیگر

Gurudutt Pendyala, PhD, is the Robert Lieberman Endowed Professor of Anesthesiology and a full Professor in the Department of Anesthesiology at the University of Nebraska Medical Center's College of Medicine. He maintains an additional appointment as Adjunct Professor in the Department of Genetics, Cell Biology and Anatomy, reflecting his interdisciplinary research approach. His research program investigates neurobiological mechanisms of addiction through several interconnected domains: Neuroinflammatory responses to psychostimulants (methamphetamine, nicotine) and opioids at synaptic levels Impacts of prenatal drug exposure on fetal synaptic development Sex-specific differences in substance abuse neurobiology MicroRNA-mediated synaptic regulation in addiction Extracellular vesicles as biomarkers and mediators in drug addiction and HIV-associated neuropathology Dr. Pendyala's recent publications (2021) demonstrate consistent focus on opioid/psychostimulant research using systems biology, epigenetic analysis, and transgenerational models. These works collectively highlight his laboratory's expertise in molecular neuroscience and neuropharmacology. He has been honored with the Robert Lieberman Endowed Professorship in recognition of his scientific contributions. His research is supported by three active NIH grants: R01DA059177 (2023-2026): Investigating placental/fetal alterations from maternal oxycodone exposure R21ES034956 (2023-2025): Examining extracellular vesicle-mediated neurotoxicity of deltamethrin R01DA046852 (2018-2023): Exploring extracellular vesicles in methamphetamine relapse mechanisms and sex differences

• Neuropsychiatry
• Inhibitory Processing Deficits
• Bipolar Disorder
• +۵ مورد دیگر

Dr. William Perry is a leading neuropsychologist and academic at UC San Diego's Department of Psychiatry, holding multiple leadership positions including Vice Chair for Program Development & Operations, Co-Director of Clinical Psychiatry, and Chief Supervising Psychologist at UCSD Medical Center. He serves as Executive Director of the National Academy of Neuropsychology and is a Fellow of both NAN and the Society for Personality Assessment. His research program focuses on inhibitory processing deficits in neuropsychiatric conditions using innovative methods: Psychophysiological assessment of unmedicated psychiatric patients Longitudinal studies of information processing deficits Translational approaches bridging human and animal models Computational analysis of behavioral dynamics Major research domains include: Bipolar disorder pathophysiology Schizophrenia neurocognition Substance use comorbidities Neurocognitive impacts of HIV and HCV Endocannabinoid system functions Recent publications (2018-2025) demonstrate strong research output in: Neuropsychopharmacology of cannabis and stimulants Computational psychiatry approaches Cross-species validation of neuropsychiatric models Neurocognitive aspects of viral infections Sensorimotor processing deficits Dr. Perry has received significant scientific recognition: Fellow, National Academy of Neuropsychology Fellow, Society for Personality Assessment Principal Investigator on multiple NIH R01 grants spanning nearly 20 years He maintains active clinical programs in neuropsychological assessment and consultation-liaison psychiatry, with specialized services for pain management, transplantation, and burn patients.

Kate Hallمشاهده پروفایل

مدرس ارشد

• Clinical Psychology
• Mental Health in Elite Sport
• Emotion Dysregulation
• +۵ مورد دیگر

Kate Hall is a Senior Lecturer at Deakin University's School of Psychology in Melbourne, Australia, with a distinguished career spanning over a decade in clinical psychology research. Previously serving as Associate Professor from 2012 to 2017, her academic trajectory demonstrates consistent advancement within the university's psychology department. Her work bridges clinical practice with real-world applications, particularly in high-performance environments. Dr. Hall's research focuses on critical intersections of mental health and performance contexts, with primary expertise in mental health in elite sport , emotion dysregulation , and vulnerable young adults with co-occurring addiction and mental health issues . Her transdiagnostic approach examines how emotion regulation deficits underpin multiple psychopathologies including substance use disorders, eating disorders, and borderline personality disorder. Recent work increasingly addresses neurodiversity within athletic populations and the development of accessible mental health interventions. Analysis of her 15 most recent publications reveals a clear research trajectory toward developing and validating accessible mental health interventions, particularly telephone-delivered treatments for substance use disorders and mental health promotion in sports contexts. Her work consistently emphasizes co-design with end-users and implementation science principles to bridge the research-practice gap. A significant portion of her recent scholarship addresses the unique mental health challenges faced by young elite athletes during developmental transitions. Dr. Hall maintains an extensive collaborative network across Australian institutions, particularly with Monash University, Queensland University of Technology, and Eastern Health. Her research program receives support from multiple Australian health agencies focused on mental health innovation and substance use treatment. She has contributed significantly to developing evidence-based guidelines for mental health in community sport settings across Australia. Her laboratory work focuses on emotion regulation mechanisms across multiple disorders, with particular emphasis on distress tolerance and negative urgency as transdiagnostic processes. Current projects include developing the ERIC (Emotion Regulation and Impulse Control) intervention for vulnerable young people and examining psychological safety frameworks in elite sport environments. Future research directions appear focused on scaling digital mental health interventions for athlete populations and refining neurodiversity-informed approaches to sports psychology practice.

• Proteomics
• Mass Spectrometry
• Protein Biochemistry
• +۶ مورد دیگر

TuKiet Lam is a Research Scientist and Director of the Keck MS & Proteomics Resource at Yale School of Medicine's Department of Molecular Biophysics and Biochemistry. He holds joint leadership of the Discovery Proteomics Core of the Yale/NIDA Neuroproteomics Center and is affiliated with Yale Cancer Center's Cancer Signaling Networks Program. Dr. Lam's research focuses on advanced mass spectrometry applications in proteomics and metabolomics. Key areas include: Protein identification and quantitative profiling in complex biological systems Analysis of posttranslational modifications (phosphorylation, ubiquitination, palmitoylation) Biomarker discovery for neurological disorders and cancers Development of novel mass spectrometry workflows His work spans diverse samples including brain tissue, cerebrospinal fluid, extracellular vesicles, and clinical specimens. Recent publications demonstrate strong research output in neurodegeneration (Alzheimer's, Parkinson's), oncology (glioblastoma), and substance use disorders. Common themes include subcellular proteomics, extracellular vesicle characterization, and multi-omic approaches integrating proteomic data with transcriptomic and clinical findings. Dr. Lam leads the Keck MS & Proteomics Resource, which provides: High-resolution tandem mass spectrometry services Protein identification and quantification Posttranslational modification analysis Targeted metabolomics The facility supports numerous NIH-funded projects and is equipped with Orbitrap mass spectrometers maintained through NIH S10 grants.

Richard Radcliffeمشاهده پروفایل

استاد

• Genetics
• Molecular Biology
• Substance Abuse
• +۴ مورد دیگر

Richard Radcliffe is a Professor at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, specializing in the genetic and molecular aspects of substance abuse disorders. Dr. Radcliffe's research focuses on understanding the genetic and molecular basis of drug and alcohol abuse. His work includes gene expression microarray analyses of central nervous system systems involved in behavioral responses to methamphetamine and alcohol, as well as QTL mapping of alcohol-related traits. His research contributes to the broader field of behavioral genetics and addiction science, aiming to identify genetic factors that influence susceptibility to substance use disorders. As a faculty member at the University of Colorado Anschutz Medical Campus, Dr. Radcliffe maintains an active research program within the Institute for Behavioral Genetics, contributing to the university's mission of advancing knowledge in pharmaceutical sciences and behavioral genetics. Dr. Radcliffe can be reached at Richard.Radcliffe@ucdenver.edu or by phone at 303-315-1595. His office is located at the Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Mail Stop C238, 12850 E. Montview Blvd. V20-3124, Aurora, CO 80045.